The European Commission authorized Novavax’s (NASDAQ: NVAX) updated COVID-19 vaccine targeting the JN.1 strain of coronavirus in the region, the company said on Wednesday.
The authorization is for use in individuals 12 years of age and older.
In August, the U.S. Food and Drug Administration granted emergency use authorization for Novavax’s shot after approving vaccines made by Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA).
Novavax offers an alternative vaccine technology with its traditional protein-based shot, unlike the messenger RNA-based vaccines, Moderna’s Spikevax and Comirnaty, which Pfizer and BioNTech jointly developed.
The updated vaccine targets the “parent strain” of currently circulating variants, and has shown robust cross-reactivity against JN.1 lineage viruses, including KP.2.3 and KP.3 subvariants, said Novavax CEO John Jacobs.
(Source: Reuters)
Jennifer Tacker is a staff writer at ABBO News. She holds a B.A. from the University of Waterloo and a B.Ed from Western University. Jennifer has been active in the stock market and crypto sector for a decade. She specializes in technical analysis and trading strategies.
